Atea Pharmaceuticals (AVIR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AVIR Atea Pharmaceuticals

Watchlist

3.670
+0.070+1.94%

Close Sep 9 16:00 ET

3.600
-0.070-1.91%

Post 20:01 ET

309.83MMarket Cap-1747P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway
newsfilter.ioAug 28 07:00 ET
Express News | Atea Pharmaceuticals Inc : Morgan Stanley Raises to Equal-Weight From Underweight
ReutersAug 13 07:38 ET
Express News | Atea Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $6.88 From $2.00
ReutersAug 13 07:38 ET
Express News | Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88
BenzingaAug 13 05:29 ET
Atea Pharmaceuticals Analyst Ratings
BenzingaAug 13 05:27 ET · Ratings
Hold Rating on Atea Pharmaceuticals Amidst Competitive Landscape and Market Uncertainties
TipRanksAug 12 16:45 ET · Ratings

Comments

Jaguar8

May 22 08:56

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Jaguar8

Apr 29 06:04

$Atea Pharmaceuticals (AVIR.US)$
NEWS
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
Atea Pharmaceuticals, Inc. announced the Phase 1 data presentation at ESCMID Global 2024, highlighting the favorable safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor. The results show no cardiotoxicity in healthy participants, supporting the drug's safety profile. Atea aims to address the unmet need for COVID-19 and HCV trea...